Ronapreve 120mg Injection Combi Pack

Ronapreve 120mg Injection Combi Pack contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days). This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021. Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries. Ronapreve 120mg Injection Combi Pack should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup. This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis). Patients should be monitored during and at least 1 hour after the injection. The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, let your doctor know immediately. Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions. Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug. This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.